Heming Li | Molecular Biology | Research Excellence Award

Dr. Heming Li | Molecular Biology | Research Excellence Award

Doctor | The first hospital of China Medical University | China

Dr. Heming Li is an oncology clinician-scientist whose research has generated 1,045 citations across 37 scientific documents with an h-index of 17, reflecting a sustained impact on translational cancer science. His work centers on liquid biopsy innovations, particularly circulating tumor cells (CTCs), tumor invasion and metastasis, and immunotherapy biomarkers in lung, gastric, and hepatobiliary cancers. Dr. Li is recognized for pioneering one of China’s earliest and most sensitive cell-surface vimentin (CSV)–based CTC detection platforms, integrating negative and positive enrichment to enhance diagnostic accuracy, reduce costs, and enable real-time monitoring of tumor evolution. His research spans EMT regulation, immune escape, metabolic reprogramming, and multi-omics characterization of metastatic pathways, leading to first-author and corresponding-author publications in high-impact journals such as The Lancet, Journal of Hematology & Oncology, Journal of Experimental & Clinical Cancer Research, Molecular Cancer, Cancer Letters, and Cell Death & Disease. He has elucidated mechanisms including IGF-IR signaling, KDM4A/STAT3-driven tumor progression, ICAM-1-mediated microenvironmental adaptation, and PD-L1 expression on CSV⁺ CTCs as a prognostic marker in gastric cancer. His recent studies have also advanced understanding of FGL1 as an immune checkpoint target and the biological significance of TROP2 in cancer therapeutics. As principal investigator, he has secured major national and provincial funding, including NSFC General and Young Programs, to study CTC-based biomarkers, immunotherapy prediction models, and metastasis-driving pathways. Through sustained contributions across liquid biopsy technology, molecular oncology, and clinically actionable biomarker development, Dr. Li has established a leading research profile shaping the future of precision cancer care.

Profile: Scopus  

Featured Publications

Irene Gómez | Molecular Biology | Best Researcher Award

Dr. Irene Gómez | Molecular Biology | Best Researcher Award

Investigador Postdoctoral at Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Spain

Irene Gómez Delgado is a passionate and highly skilled postdoctoral researcher working at the Health Research Foundation of Clínico San Carlos Hospital, where she specializes in biomedicine, medical microbiology, and environmental risks. She has shown exceptional dedication to scientific discovery, focusing on the genetic and molecular basis of complex diseases, particularly in the area of immunology and nephrology. Irene’s collaborative spirit, commitment to rigorous methodology, and enthusiasm for public science engagement have marked her as an emerging leader in her field.

profile

orcid

Education

Irene Gómez Delgado’s academic journey reflects both excellence and depth, beginning with her Bachelor’s Degree in Biology from Universidad Complutense de Madrid, earned in 2016. She continued her academic pursuit with a Master’s Degree in Immunology Research from the same university in 2017, equipping her with advanced knowledge of immune system mechanisms. She culminated her formal education by earning a PhD in Molecular Bioscience at Universidad Autónoma de Madrid in 2022, where she developed a strong foundation in molecular biology, genetic research, and experimental design, all of which continue to influence her contributions to biomedical science.

Experience

Irene has steadily advanced her scientific career through key research roles, beginning as a predoctoral researcher at the Health Research Foundation of La Paz University Hospital from 2017 to 2022, where she gained comprehensive experience in molecular biology, laboratory supervision, and project execution. Since 2022, she has been working as a postdoctoral researcher at Clínico San Carlos Hospital’s Laboratory of Genetic and Molecular Basis of Complex Diseases. Alongside her research, Irene has co-directed Master’s Final Projects and supervised undergraduate students and laboratory technicians, showing strong leadership and mentorship capabilities.

Research Interest

Irene’s research interests lie primarily in understanding the molecular and genetic mechanisms underlying immunological and nephrological diseases. Her scientific focus includes studying complement system dysregulation, genetic variants related to immune system proteins, and mitochondrial alterations in immune cells. Her work also extends to infectious disease complications, including severe COVID-19 immune responses, making her research impactful for both rare disease understanding and global health challenges.

Award

Irene Gómez Delgado has been recognized for her scientific achievements through multiple awards. In 2023, she was honored with the Extraordinary Doctorate Award by Universidad Autónoma de Madrid, celebrating the outstanding quality and impact of her doctoral work. She also received the Poster Communication Award from the European Complement Network in 2022 for her contribution at the 18th European Meeting on Complement in Human Disease held in Bern, Switzerland. These awards highlight her scientific excellence and growing reputation in the immunology and nephrology research communities.

Publication

Dr. Gómez Delgado has co-authored several peer-reviewed scientific articles that contribute to the advancement of biomedical research.

Long term mitochondrial and metabolic impairment in lymphocytes of subjects who recovered after severe COVID-19 — published in 2025 in Cell Biology and Toxicology.

Tigecycline Opposes Bortezomib Effect on Myeloma Cells Decreasing Mitochondrial Reactive Oxygen Species Production — published in 2024 in International Journal of Molecular Sciences.

Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome — published in 2021 in Frontiers in Immunology.

Low factor H-related 5 levels contribute to infection-triggered haemolytic uraemic syndrome and membranoproliferative glomerulonephritis — published in 2021 in Clinical Kidney Journal.

High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B — published in 2018 in Frontiers in Immunology.

Contribution of functional and quantitative genetic variants of Complement Factor H and Factor H-Related (FHR) proteins on renal pathology — published in 2022 in Nefrología.

Altered expression of FHR-1 and FHR-2 glycoforms in IgA nephropathy patients — published in 2024 in European Journal of Immunology (Meeting Abstract).

Conclusion

Dr. Irene Gómez Delgado exemplifies the qualities of a leading researcher through her pioneering contributions to immunology and molecular medicine, her active engagement in scientific dissemination, and her commitment to mentorship and collaborative research. Her career trajectory reflects an unwavering pursuit of knowledge and societal impact, which makes her a deserving and inspiring nominee for the Research for Best Researcher Award.